Alkermes launches a phase 2 trial of oral orexin-2 agonist ALKS 7290 to boost antidepressant response in major depressive disorder, assessing safety and symptom relief.
News|Articles|April 23, 2026
Rational Off-Label Prescribing: A Review With Joseph F. Goldberg, MD, and Henry Nasrallah, MD
Author(s)Joseph F. Goldberg, MD, Henry Nasrallah, MD
Psychiatry experts explain why off-label psych meds and polypharmacy can be essential.
Advertisement
Advertisement
Joseph F. Goldberg, MD, sat down with Henry Nasrallah, MD, to discuss the essentials of off-label prescribing and uses of
Related to this article
BCG vaccination curbs tau tangles in mice by boosting microglial cleanup, fueling hopes for human trials to reduce dementia risk.
GLP-1 weight-loss drugs may worsen eating disorders or mask symptoms; experts urge careful screening, specialist referral, and monitoring before, during, and after use.
Psychedelic trials often exclude real-world comorbidities; clinicians must weigh blinding limits, dosing durability, support needs, safety risks, and uneven system readiness.
GLP-1 drugs may quiet cravings by reshaping brain reward and satiety signals, reducing food-seeking drive and binge-like eating, while long-term effects remain unclear.
New automated connectomics maps synapses across circuits, revealing how inhibitory neuron subtypes shape decision-making and may explain circuit dysfunction in psychiatric disorders.
When an antidepressant seems to stop working, the patient’s deterioration is real. The explanation may be less certain.
Explore evolving ethical challenges of long-acting injectable antipsychotics, weighing relapse prevention against coercion, stigma, incentives, and racial equity in clinical practice.
Advertisement
Advertisement